Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio

American Society of Clinical Oncology, Journal of Clinical Oncology, 9(34), p. 1017-1018, 2016

Journal article published in 2016 by Alice Indini, Massimo Di Nicola, Michele Del Vecchio

, Filippo De Braud

This paper is made freely available by the publisher.

Full text: Download

Preprint: archiving forbidden

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by